- Cytovance Biologics has expanded its upstream process development services by adding perfusion capabilities to support biologics development.
- The new capability complements traditional fed-batch manufacturing and provides sponsors with greater flexibility for monoclonal antibodies, recombinant proteins, and other biologic modalities.
Cytovance Biologics has expanded its upstream process development offering with the addition of perfusion capabilities. The new service complements the company’s existing fed-batch manufacturing approach and provides biopharmaceutical companies with an additional option for developing biologics manufacturing processes. The CDMO said the capability is intended to support programs requiring higher productivity, longer cell culture durations, and increased process flexibility.
Perfusion technology continuously supplies fresh media while removing spent media, allowing cell cultures to remain productive for longer periods compared with traditional fed-batch processes. According to Cytovance, the approach can improve productivity, maintain more consistent culture conditions, and reduce the accumulation of metabolic byproducts that may affect product quality. The company said the new capability will support early process development for monoclonal antibodies, recombinant proteins, and other biologic modalities.
“Our goal is to continue expanding the technologies and expertise available to clients as the industry evolves. By integrating perfusion into our development platform, we’re giving sponsors greater flexibility while positioning Cytovance to support the future of biologics manufacturing.”
Fuad Haddadin, Ph.D., Head of Research & Development at Cytovance Biologics.
Cytovance said the addition of perfusion enables clients to evaluate multiple upstream manufacturing strategies and select the most appropriate approach for their development programs. The company emphasized that perfusion is intended to complement, rather than replace, fed-batch manufacturing as part of its contract manufacturing and process development services.
The investment builds on Cytovance’s recent expansion of its in-house cell line development and formulation development services, further broadening its integrated CDMO offering for biopharmaceutical developers.
